预测2024/2025季节美国符合条件婴幼儿对尼塞韦单抗的最大潜在需求
研究将2023年3月至2025年3月所有出生儿按周分组,依据年龄、体重、出生月份、母体接种和重症风险划分资格,建立模型预测2024/2025季节尼塞韦单抗需求。
要点
- 预计有资格的剂量中48%为100毫克剂型。
- 总资格预测可用于指导生产目标并避免尼塞韦单抗短缺。
研究设计与样本
- 2023/2024年冬季建立模型,将2023年3月至2025年3月所有出生儿按周分组,依据资格标准划分并计算各组资格。
主要发现
- 预计有资格的剂量中48%为100毫克剂型。
关键数值与推荐
- 儿童根据年龄、体重、出生月份、母体接种和重症风险,有资格接种一剂50毫克、一剂100毫克或两剂100毫克尼塞韦单抗。
临床怎么用
- 总资格预测可用于指导生产目标并避免尼塞韦单抗短缺。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Nirsevimab is a long-acting monoclonal antibody that protects infants and young children against severe respiratory syncytial virus (RSV) disease. Children are eligible for one 50 mg dose, one 100 mg dose, or two 100 mg doses of nirsevimab based on age, weight, time of year, maternal vaccination, and risk of severe disease. In winter 2023/2024, we developed a model to project the number of nirsevimab doses needed to immunize all eligible U.S. children during the 2024/2025 season. We grouped all births from March 2023 through March 2025 into weekly cohorts, partitioned those cohorts based on eligibility criteria, and computed eligibility for each partition. In the absence of maternal RSV vaccination, we estimated U.S. children would be eligible to receive 4.3 million nirsevimab doses in 2024/2025, of which 48% would be 100 mg doses. Projections of total eligibility can be used to inform production goals and avoid shortages of nirsevimab.
引用
- Olesen SW, Holmdahl I, Ortega-Sanchez IR, et al. Projecting maximum potential demand for nirsevimab to protect eligible US infants and young children against respiratory syncytial virus in the 2024/2025 season. Vaccine. 2025. PMID: 40209626. doi:10.1016/j.vaccine.2025.127109
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。